Doudna and Charpentierand their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna

Reporter: Aviva Lev-Ari, PhD, RN


The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of all types. The technology was invented by Jennifer Doudna, a UC Berkeley professor of molecular and cell biology, Charpentier, now director of the Max Planck Institute for Infection Biology in Berlin, and their colleagues. Applications include treatment of various human diseases, as well as veterinary, agricultural and other biotech applications. The European patent would cover some 40 countries, including France, Germany, Italy, Spain, the Netherlands and Switzerland.

The EPO has stated its intent to grant a patent with claims that encompass all cells, despite objections from third parties, including the Broad Institute, a joint research institute of Harvard University and the Massachusetts Institute of Technology.

“We are excited that this patent will issue based on the foundational research we published with Emmanuelle Charpentier and the rest of our team. We look forward to the continued applications of gene-editing technology to solve problems in human health and agriculture,” said Doudna, who is a Howard Hughes Medical investigator at UC Berkeley.

The UC patent application to the EPO was substantially the same as the UC patent application filed in the United States. In the U.S., UC claims covering the use of single-guide CRISPR-Cas9 technology in any setting were found to be allowable by the U.S. Patent & Trademark Office, and were placed in an interference with patents owned by the Broad Institute that cover use of the technology in eukaryotic cells. An interference is a formal legal proceeding before the Patent Trial and Appeal Board (PTAB) to determine who was the first to invent.

“We disagree with the recent PTAB decision to terminate the interference between claims of the UC and the Broad Institute, and we are keeping all of our options open, including the possibility of an appeal,” Penhoet said. “We remain confident that when the inventorship question is finally answered, the Doudna and Charpentier teams will prevail.”




Other related articles published in this Open Access Online Scientific Journal include the following:

Gene Editing Consortium of Biotech Companies: CRISPR Therapeutics $CRSP, Intellia Therapeutics $NTLA, Caribou Biosciences, ERS Genomics, UC, Berkeley (Doudna’s IP) and University of Vienna (Charpentier’s IP), is appealing the decision ruled that there was no interference between the two sides, to the U.S. Court of Appeals for the Federal Circuit, targeting patents from The Broad Institute.



Keyword Search: CRISPR – 247 articles in pharmaceuticalintelligence.com



2017 award recipients including Thomas S. Kilduff, PhD, Director, Center for Neuroscience at SRI International in Menlo Park, California


Reporter: Aviva Lev-Ari, PhD, RN

I was Director of the Business and Economic Statistics Program at SRI International in Menlo Park, California, 1985-1988.

Sleep Research Society announces 2017 award recipients

Sleep Research Society
Friday, April 28, 2017

DARIEN, IL – Several of the world’s leading sleep and circadian scientists were selected as recipients of the 2017 Sleep Research Society awards, which will be presented Monday, June 5, during the plenary session of SLEEP 2017, the 31st annual meeting of the Associated Professional Sleep Societies LLC (APSS) in Boston.

“The Sleep Research Society awards recognize individuals who have made significant and lasting contributions to sleep and circadian science,” said SRS President Sean P.A. Drummond, PhD. “I congratulate each of the recipients of the 2017 awards and appreciate all that they have done to help the SRS achieve its mission to advance sleep and circadian science.”

The 2017 SRS award recipients, who were selected by the SRS board of directors, are:

Thomas S. Kilduff, PhD
Distinguished Scientist Award for significant, original and sustained scientific contributions of a basic, clinical or theoretical nature to the sleep and circadian research field, made over an entire career
Dr. Kilduff directs the Center for Neuroscience at SRI International in Menlo Park, California. He is co-discoverer of the neuropeptide hypocretin (orexin), a key neurotransmitter in the maintenance of wakefulness. His group at SRI has identified a cortical interneuron population that is activated during sleep in proportion to homeostatic sleep drive, and their work also focuses on therapeutic development for insomnia and narcolepsy.

As the SRS Distinguished Scientist Award recipient, Dr. Kilduff also receives the honor of presenting an invited lecture at the SLEEP 2017 annual meeting. He will present the lecture, “Identifying Novel Sleep/Wake Targets: Hypocretin/Orexin, Cortical nNOS Neurons, and TAAR1,” on Tuesday, June 6, at the Hynes Convention Center in Boston.

Niels C. Rattenborg, PhD
Outstanding Scientific Achievement Award for novel and seminal discoveries of a basic, clinical or theoretical nature that have made a significant impact on the sleep field
Dr. Rattenborg is the leader of the Avian Sleep Group at the Max Planck Institute for Ornithology (MPIO) in Seewiesen, Germany. His research, published in August 2016 in the journal Nature Communications, was the first to demonstrate sleep in flying birds. Using electroencephalogram recordings of great frigatebirds flying over the ocean for up to 10 days, his team found that the birds can sleep with either one hemisphere at a time or both hemispheres simultaneously. However, while in flight they sleep for a much smaller percentage of time than they do while on land, which challenges the dominant view that large daily amounts of sleep are required to maintain adaptive performance.

Colin A. Espie, PhD, DSc
Mary A. Carskadon Outstanding Educator Award for excellence in the field of education related to sleep medicine and sleep research
Dr. Espie is professor of sleep medicine in the Nuffield Department of Clinical Neuroscience and a Fellow of Somerville College at the University of Oxford in England. He is research director of the Experimental and Clinical Sleep Medicine program within the Sleep & Circadian Neuroscience Institute and clinical director of the Oxford Online Program in Sleep Medicine.

Photos are available upon request. For more information, please contact Specialty Society Coordinator Barbara Hoeft at 630-737-9700, ext. 9321, or bhoeft@srsnet.org.

About the Sleep Research Society
The Sleep Research Society (SRS) is a professional membership society that advances sleep and circadian science. The SRS provides forums for the exchange of information, establishes and maintains standards of reporting and classifies data in the field of sleep research, and collaborates with other organizations to foster scientific investigation on sleep and its disorders. The SRS also publishes the peer-reviewed, scientific journal SLEEP.



FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com,

Top Articles by Author and by e-Views >1,000,

4/27/2012 to 4/27/2017


Editor-in-Chief: Aviva Lev-Ari, PhD, RN


FIVE years of e-Scientific Publishing  –  Top Articles by e-Views >1,000 for all days ending 2017-04-27 (Summarized)


Article Title
  Views All Time Author

Home page / Archives



Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 15,461 Larry H. Bernstein, MD, FCAP
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 10,005  

Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Recent comprehensive review on the role of ultrasound in breast cancer management 7,513 Dror Nir, PhD
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 6,721 Tilda Barliya, PhD
Our TEAM 5,722 Aviva Lev-Ari, PhD, RN
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 5,380 Tilda Barliya, PhD
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 4,379 Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,077 Ziv Raviv, PhD
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 3,847 Zohi Sternberg, PhD
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 3,609 Aviva Lev-Ari, PhD, RN
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms 3,456 Larry H. Bernstein, MD, FCAP, Stephen J Williams, PhD, Aviral Vatsa, PhD, et al.
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad 3,330 Demet Sag, PhD
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo 3,215 Stephen J Williams, PhD
Founder 3,131 Aviva Lev-Ari, PhD, RN
BioMed e-Series 3,005 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN,

et al.

Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology 2,866 Tilda Barliya, PhD
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 2,854 Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I 2,677 Larry H. Bernstein, MD, FCAP
VISION 2,651 Aviva Lev-Ari, PhD, RN
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community 2,602 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Funding, Deals & Partnerships 2,506 Aviva Lev-Ari, PhD, RN
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 2,461 Stephen J Williams, PhD
Bone regeneration and nanotechnology 2,446 Tilda Barliya, PhD
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging 2,400 Dror Nir, PhD
“The Molecular pathology of Breast Cancer Progression” 2,315 Tilda Barliya, PhD
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation 2,240 Larry H. Bernstein, MD, FCAP
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) 2,190 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Targeting the Wnt Pathway [7.11] 2,162 Larry H. Bernstein, MD, FCAP
In focus: Circulating Tumor Cells 2,151 Ritu Saxena, PhD
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) 2,110 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 2,100 Stephen J Williams, PhD
Journal PharmaceuticalIntelligence.com 2,068 Aviva Lev-Ari, PhD, RN and  et al.
About 2,044 Aviva Lev-Ari, PhD, RN
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment 2,028 Sudipta Saha, PhD
Interaction of enzymes and hormones 1,994 Larry H. Bernstein, MD, FCAP
Problems of vegetarianism
1,908 Sudipta Saha, PhD
DNA Structure and Oligonucleotides 1,905 Larry H. Bernstein, MD, FCAP
Biosimilars: CMC Issues and Regulatory Requirements 1,813 Aviva Lev-Ari, PhD, RN
CD47: Target Therapy for Cancer 1,763 Tilda Barliya, PhD
Lipid Metabolism 1,761 Larry H. Bernstein, MD, FCAP
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes 1,761 Aviva Lev-Ari, PhD, RN
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) 1,725 Tilda Barliya, PhD
Non-small Cell Lung Cancer drugs – where does the Future lie? 1,720 Ritu Saxena, PhD
A Primer on DNA and DNA Replication 1,720 Larry H. Bernstein, MD, FCAP
Introduction to Tissue Engineering; Nanotechnology applications 1,711 Tilda Barliya, PhD
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node 1,667 Tilda Barliya, PhD
Nitric Oxide Function in Coagulation – Part II 1,614 Larry H. Bernstein, MD, FCAP
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research 1,603 Stephen J Williams, PhD
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® 1,578 Aviva Lev-Ari, PhD, RN
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB 1,542 Aviva Lev-Ari, PhD, RN
The role of biomarkers in the diagnosis of sepsis and patient management 1,500 Larry H. Bernstein, MD, FCAP
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers 1,475 Aviva Lev-Ari, PhD, RN
Nanotechnology and MRI imaging 1,470 Tilda Barliya, PhD
Baby’s microbiome changing due to caesarean birth and formula feeding 1,457 Aviva Lev-Ari, PhD, RN
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions 1,453 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays 1,424 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? 1,417 Aviva Lev-Ari, PhD, RN
Neonatal Pathophysiology 1,412 Larry H. Bernstein, MD, FCAP
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) 1,408 Aviva Lev-Ari, PhD, RN
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases 1,396 Justin D. Pearlman, MD, PhD, FACC
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase 1,384 Demet Sag, PhD
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack 1,360 Aviva Lev-Ari, PhD, RN
Monoclonal Antibody Therapy and Market 1,352 Demet Sag, PhD
Mitochondrial Damage and Repair under Oxidative Stress 1,315 Larry H. Bernstein, MD, FCAP
Closing the Mammography gap 1,292 Dror Nir, PhD
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease 1,288 Aviva Lev-Ari, PhD, RN
Update on FDA Policy Regarding 3D Bioprinted Material 1,286 Aviva Lev-Ari, PhD, RN
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? 1,276 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN, Director and Founder 1,250 Aviva Lev-Ari, PhD, RN
Diagnostic Evaluation of SIRS by Immature Granulocytes 1,249 Larry H. Bernstein, MD, FCAP
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) 1,238 Larry H. Bernstein, MD, FCAP
Signaling and Signaling Pathways 1,235 Larry H. Bernstein, MD, FCAP
Crucial role of Nitric Oxide in Cancer 1,215 Ritu Saxena, PhD
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 1,211 Aviva Lev-Ari, PhD, RN
Mitochondrial fission and fusion: potential therapeutic targets? 1,203 Ritu Saxena, PhD
Diet and Diabetes 1,186 Larry H. Bernstein, MD, FCAP
Mitochondrial Dynamics and Cardiovascular Diseases 1,171 Ritu Saxena, PhD
Nanotechnology and Heart Disease 1,159 Tilda Barliya, PhD
Nitric Oxide and Immune Responses: Part 2 1,153 Aviral Vatsa, PhD
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery 1,153 Aviva Lev-Ari, PhD, RN
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments 1,149 Larry H. Bernstein, MD, FCAP
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly 1,128 Aviva Lev-Ari, PhD, RN
Scientific and Medical Affairs Chronological CV 1,127 Aviva Lev-Ari, PhD, RN
Assessing Cardiovascular Disease with Biomarkers 1,122 Larry H. Bernstein, MD, FCAP
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing 1,116 Stephen J Williams, PhD
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors 1,112 Stephen J Williams, PhD
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function 1,111 Larry H. Bernstein, MD, FCAP
Nanotechnology and HIV/AIDS treatment 1,109 Tilda Barliya, PhD
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin 1,107 Aviva Lev-Ari, PhD, RN
Ultrasound-based Screening for Ovarian Cancer 1,105 Dror Nir, PhD
Stenting for Proximal LAD Lesions 1,082 Aviva Lev-Ari, PhD, RN
Treatment of Refractory Hypertension via Percutaneous Renal Denervation 1,082 Aviva Lev-Ari, PhD, RN
Nitric Oxide and it’s impact on Cardiothoracic Surgery 1,079 Tilda Barliya, PhD
Wnt/β-catenin Signaling [7.10] 1,078 Larry H. Bernstein, MD, FCAP
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism 1,068 Larry H. Bernstein, MD, FCAP,             Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands 1,063 Aviva Lev-Ari, PhD, RN
Patiromer – New drug for Hyperkalemia 1,054 Aviva Lev-Ari, PhD, RN
Isoenzymes in cell metabolic pathways 1,048 Larry H. Bernstein, MD, FCAP
Sex Hormones 1,039 Larry H. Bernstein, MD, FCAP
LPBI Group 1,027 Aviva Lev-Ari, PhD, RN
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty 1,027 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I 1,020 Aviral Vatsa, PhD
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents 1,015 Aviral Vatsa, PhD
Ovarian Cancer and fluorescence-guided surgery: A report 1,012 Tilda Barliya, PhD
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation 1,012 Aviva Lev-Ari, PhD, RN
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model 1,011 Anamika Sarkar, PhD
New England Compounding Center: A Family Business 1,008 Alan F. Kaul, PharmD
Integrins, Cadherins, Signaling and the Cytoskeleton 1,003 Larry H. Bernstein, MD, FCAP

Tax Cuts Potential Impact on Overseas (ex-US accounts) by Top 9 Biopharma holdings of $133B in M&A 

Reporter: Aviva Lev-Ari, PhD, RN


Amgen has been sheltering a cache of about $35 billion in ex-US accounts, according to some numbers that EvercoreISI’s Umer Raffat put together as he began assessing the impact tax reform could have on the top players in overseas holdings.



The top 9 overseas accounts in biopharma hold $133B in M&A firepower by john carroll April 27, 2017 06:42 AM EDT, Updated: 08:15 AM

Pharmacotyping Pancreatic Cancer Patients in the Future: Two Approaches – ORGANOIDS by David Tuveson and Hans Clevers and/or MICRODOSING Devices by Robert Langer

Curator: Aviva Lev-Ari, PhD, RN


This curation provides the resources for edification on Pharmacotyping Pancreatic Cancer Patients in the Future


  • Professor Hans Clevers at Clevers Group, Hubrecht University


  • Prof. Robert Langer, MIT


Langer’s articles on Drug Delivery


organoids, which I know you’re pretty involved in with Hans Clevers. What are your plans for organoids of pancreatic cancer?

Organoids are a really terrific model of a patient’s tumour that you generate from tissue that is either removed at the time of surgery or when they get a small needle biopsy. Culturing the tissue and observing an outgrowth of it is usually successful and when you have the cells, you can perform molecular diagnostics of any type. With a patient-derived organoid, you can sequence the exome and the RNA, and you can perform drug testing, which I call ‘pharmacotyping’, where you’re evaluating compounds that by themselves or in combination show potency against the cells. A major goal of our lab is to work towards being able to use organoids to choose therapies that will work for an individual patient – personalized medicine.

Organoids could be made moot by implantable microdevices for drug delivery into tumors, developed by Bob Langer. These devices are the size of a pencil lead and contain reservoirs that release microdoses of different drugs; the device can be injected into the tumor to deliver drugs, and can then be carefully dissected out and analyzed to gain insight into the sensitivity of cancer cells to different anticancer agents. Bob and I are kind of engaged in a friendly contest to see whether organoids or microdosing devices are going to come out on top. I suspect that both approaches will be important for pharmacotyping cancer patients in the future.

From the science side, we use organoids to discover things about pancreatic cancer. They’re great models, probably the best that I know of to rapidly discover new things about cancer because you can grow normal tissue as well as malignant tissue. So, from the same patient you can do a comparison easily to find out what’s different in the tumor. Organoids are crazy interesting, and when I see other people in the pancreatic cancer field I tell them, you should stop what you’re doing and work on these because it’s the faster way of studying this disease.


Other related articles on Pancreatic Cancer and Drug Delivery published in this Open Access Online Scientific Journal include the following:


Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com

Curator: Aviva Lev-Ari, PhD, RN


Keyword Search: “Pancreatic Cancer” – 275 Article Titles


Keyword Search: Drug Delivery: 542 Articles Titles


Keyword Search: Personalized Medicine: 597 Article Titles


  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015





Reporter and Curator: Dr. Sudipta Saha, Ph.D.


Babies born at or before 25 weeks have quite low survival outcomes, and in the US it is the leading cause of infant mortality and morbidity. Just a few weeks of extra ‘growing time’ can be the difference between severe health problems and a relatively healthy baby.


Researchers from The Children’s Hospital of Philadelphia (USA) Research Institute have shown it’s possible to nurture and protect a mammal in late stages of gestation inside an artificial womb; technology which could become a lifesaver for many premature human babies in just a few years.


The researchers took eight lambs between 105 to 120 days gestation (the physiological equivalent of 23 to 24 weeks in humans) and placed them inside the artificial womb. The artificial womb is a sealed and sterile bag filled with an electrolyte solution which acts like amniotic fluid in the uterus. The lamb’s own heart pumps the blood through the umbilical cord into a gas exchange machine outside the bag.


The artificial womb worked in this study and after just four weeks the lambs’ brains and lungs had matured like normal. They had also grown wool and could wiggle, open their eyes, and swallow. Although this study is looking incredibly promising but getting the research up to scratch for human babies still requires a big leap.


Nevertheless, if all goes well, the researchers hope to test the device on premature humans within three to five years. Potential therapeutic applications of this invention may include treatment of fetal growth retardation related to placental insufficiency or the salvage of preterm infants threatening to deliver after fetal intervention or fetal surgery.


The technology may also provide the opportunity to deliver infants affected by congenital malformations of the heart, lung and diaphragm for early correction or therapy before the institution of gas ventilation. Numerous applications related to fetal pharmacologic, stem cell or gene therapy could be facilitated by removing the possibility for maternal exposure and enabling direct delivery of therapeutic agents to the isolated fetus.








































LAUREATES 2017 – – The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University

Reporter: Aviva Lev-Ari, PhD, RN



The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University.

The Dan David Prize recognizes and encourages innovative and interdisciplinary research that cuts across traditional boundaries and paradigms. It aims to foster universal values of excellence, creativity, justice, democracy and progress and to promote the scientific, technological and humanistic achievements that advance and improve our world.

The Dan David Prize covers three time dimensions – Past, Present and Future – that represent realms of human achievement. Each year the International Board chooses one field within each time dimension. Following a review process by independent Review Commitees comprised of renowned scholars and professionals, the International Board then chooses the laureates for each field.

The Past refers to fields that expand knowledge of former times.
The Present recognizes achievements that shape and enrich society today.
The Future focuses on breakthroughs that hold great promise for improvement of our world.

Three prizes of one million US dollars each are granted annually in the fields chosen for the three time dimensions. The prizes are granted to individuals or institutions with proven, exceptional, distinct excellence in the sciences, arts, humanities, public service and business, that have made and continue to make an outstanding contribution to humanity on the basis of merit, without discrimination of gender, race, religion, nationality, or political affiliation.

The Dan David Pize laureates donate 10% of their prize money to post graduate students in their respective fields, thereby contributing to the community and fostering a new generation of scholars. It is also unique in its outreach efforts to the wider community. Since its inception, the Dan David Prize has embarked upon two exciting innitiatives:

  • The Dan David Prize, in conjunction with the Unit for Science Oriented Youth at Tel Aviv University has initiated the ‘Name Your Hero’ Essay Competition for High School Youth throughout Israel. High school students are encouraged to make a difference and present their choice of candidate and/or suggestions for fields, to the mutual benefit of the Dan David Prize and the students; the fields selected for a given year are influenced by the students’ input and the students’ scholarship and creative writing skills are advanced.
  • A Scholars Forum has been established comprised of Dan David Prize scholarship recipients worldwide doing research in the various fields selected since the inception of the Dan David Prize. This forum serves as a platform for Dan David Prize scholars to discuss research topics, present individual research and exchange ideas and suggestions

For a better understanding of the drive behind the creation of the Prize, press here for Mr. Dan David’s speech at the Inaugurational Ceremony of the Prize, on May 12th 2001.



Max Planck Institute for Evolutionary Anthropology


Harvard Medical School







PROF. NEIL GEHRELS (1952-2017)

PROF. NEIL GEHRELS (1952-2017)
NASA Goddard Space Flight Center


California Institute of Technology


Astronomical Observatory Warsaw University


view online »

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.








Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only